News | November 03, 2021
WHO issues emergency use listing for Covaxin
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Subscribe To Our Newsletter & Stay Updated
